Synthetic Approaches to the New Drugs Approved During 2021

被引：13

作者：

McInturff, Emma L. ^{[1
]}

France, Scott P. ^{[2
]}

Leverett, Carolyn A. ^{[1
]}

Flick, Andrew C. ^{[3
]}

Lindsey, Erick A. ^{[3
]}

Berritt, Simon ^{[1
]}

Carney, Daniel W. ^{[3
]}

DeForest, Jacob C. ^{[4
]}

Ding, Hong X. ^{[5
]}

Fink, Sarah J. ^{[6
]}

Gibson, Tony S. ^{[3
]}

Gray, Kaitlyn ^{[1
]}

Hubbell, Aran K. ^{[1
]}

Johnson, Amber M. ^{[1
]}

Liu, Yiyang ^{[1
]}

Mahapatra, Subham ^{[1
]}

McAlpine, Indrawan J. ^{[7
]}

Watson, Rebecca B. ^{[4
]}

O'Donnell, Christopher J. ^{[1
]}

机构：

[1] Pfizer Worldwide Res & Dev, Groton Labs, Groton, CT 06340 USA

[2] Merck & Co Inc, Proc Res & Dev, Rahway, NJ 07065 USA

[3] Takeda Pharmaceut, San Diego, CA 92121 USA

[4] Pfizer Worldwide Res & Dev, La Jolla Labs, San Diego, CA 92121 USA

[5] Pharmacodia Beijing Co Ltd, Beijing 100085, Peoples R China

[6] Takeda Pharmaceut, Cambridge, MA 02142 USA

[7] Genesis Therapeut, San Diego, CA 92121 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 66卷 / 15期

关键词：

ATOPIC-DERMATITIS; MOLYBDENUM COFACTOR; PHOSPHODIESTERASE-4; INHIBITOR; BIOLOGICAL EVALUATION; RECEPTOR ANTAGONIST; DOUBLE-BLIND; POTENT; CANCER; HYDROCHLORIDE; MOLNUPIRAVIR;

D O I：

10.1021/acs.jmedchem.3c00501

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Each year, new drugs are introduced to the market, representingstructures that have affinity for biological targets implicated inhuman diseases and conditions. These new chemical entities (NCEs),particularly small molecules and antibody-drug conjugates,provide insight into molecular recognition and serve as potentialleads for the design of future medicines. This annual review is partof a continuing series highlighting the most likely process-scalesynthetic approaches to 35 NCEs that were first approved anywherein the world during 2021.

引用

页码：10150 / 10201

页数：52

共 50 条

[21] Synthetic Routes to Approved Drugs Containing a Spirocycle
Moshnenko, Nazar
Kazantsev, Alexander
Chupakhin, Evgeny
Bakulina, Olga
Dar'in, Dmitry
[J]. MOLECULES, 2023, 28 (10):
[22] Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update
Sun, Lu
Nie, Peng
Luan, Li
Herdewijn, Piet
Wang, Ya-Tao
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 261
[23] Unlocking the synthetic approaches and clinical application of approved small-molecule drugs for gastrointestinal cancer treatment: A comprehensive exploration
Li, Xiao-Jing
Nie, Peng
Herdewijn, Piet
Sun, Jian-Gang
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 262
[24] Structure-property Relationships Reported for the New Drugs Approved in 2023
Choi, Kihang
[J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2024, 24 (20) : 1822 - 1833
[25] Acute Migraine Therapy: New Drugs and New Approaches
Monteith, Teshamae S.
Goadsby, Peter J.
[J]. CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2011, 13 (01) : 1 - 14
[26] Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications
Liu, He-Nan
Zhu, Ying
Chi, Yuan
Sun, Fei-Fei
Shan, Li-Shen
Wang, Ya-Tao
Dai, Bing
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 276
[27] New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents
Toussirot, Eric
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (03) : 275 - 282
[28] New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies
Morley, Kirsten C.
Perry, Christina J.
Watt, Joshua
Hurzeler, Tristan
Leggio, Lorenzo
Lawrence, Andrew J.
Haber, Paul
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (10) : 1291 - 1303
[29] Synthesis and clinical application of new drugs approved by FDA in 2022
Zhang, Jing-Yi
Wang, Ya-Tao
Sun, Lu
Wang, Sai-Qi
Chen, Zhe-Sheng
[J]. MOLECULAR BIOMEDICINE, 2023, 4 (01):
[30] Characteristics of clinical trials of new oncology drugs approved in China
Yang, Jing
Yang, Ji
Hu, Yuan-Jia
[J]. CANCER, 2024, 130 (05) : 671 - 682

← 1 2 3 4 5 →